arrow
R

Riccardo Cuoghi Costantini

University Hospital of Modena
H指数:8
被引数:239

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Trajectory-Adaptive Model of Early Palliative Care in AML and High-Risk MDS: Real-World Evidence on Core Components and Care Outcomes

急性髓系白血病和高风险骨髓增生异常综合征早期姑息治疗的轨迹适应性模型:关于核心组成和护理结局的真实世界证据

2026-09-300
OA
Timing of endometrial biopsy for chronic endometritis diagnosis: CD138+ and CD56+ cell variability throughout the menstrual cycle

子宫内膜活检诊断慢性子宫内膜炎的时间:月经周期中CD138+和CD56+细胞的变异性

2026-01-010
PRE
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer

BRCA突变HR阳性/HER2阴性晚期乳腺癌在接受CDK4/6抑制剂治疗后使用PARP抑制剂的实效性

2025-12-130
OAAI
Multiplex engineering using microRNA-mediated gene silencing in CAR T cells

基于微RNA介导的基因沉默的CAR T细胞多路复用工程

2025-08-210
OA
Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology

数字性溃疡在系统性硬化症患者中的患病率及临床意义:意大利风湿病学会SPRING注册研究中的真实世界经验

2025-05-150
OA
Early Palliative Care, Goals of Care Conversations and Quality EOL Care in Acute Leukemia and HR-MDS

早期姑息治疗、照护目标讨论和急性白血病及HR-MDS中的临终关怀质量

2025-04-030
PRE
Colchicine treatment in amyotrophic lateral sclerosis: safety, biological and clinical effects in a randomized clinical trial

秋水仙碱治疗肌萎缩侧索硬化: 安全性、生物学和临床效果的随机临床试验

2024-09-051
OAAI
Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma
2024-08-010
OAAI
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study

新辅助帕妥珠单抗、曲妥珠单抗和标准化疗治疗HER2-positive早期乳腺癌的安全性和有效性分析: 来自NeoPowER研究的真实数据

2024-06-151
OAAI
Cognitive, behavioral and socio-communication skills as predictors of response to Early Start Denver Model: a prospective study in 32 young children with Autism Spectrum Disorder
2024-05-301
OAAI